Conferences & Events

Lung Cancer 2017: Progress and Future Directions

Date & Location

Saturday, November 4, 2017 7:15 AM - 3:35 PM   Renaissance Washington DC Dupont Circle Hotel, Washington, DC


Medical Oncology, Nuclear Medicine, Pathology, Pulmonology, Radiation Oncology, Radiology, Surgery


This one-day symposium will provide a comprehensive update on recent advances in the care of patients with thoracic malignancies. There is increasing recognition of a gap between evidence-based guidelines and clinical practice, with research demonstrating that up to 40% of patients fail to receive effective therapies and 20% of patients receive therapies that are ineffective or even harmful.  Reducing these gaps leads to reduction in patient morbidity and mortality, and decreased health care costs. With the rapid advances in thoracic oncology, this symposium attempts to crystallize current knowledge and provide critical information and key take-home points to the busy practicing clinician involved in the care of patients with thoracic malignancies. Key focus topics will include the identification of patients at high risk for lung cancer, understand the upcoming changes to lung cancer staging using the IASLC 8th edition guidelines, patient selection for multi-modality therapy in lung cancer, mesothelioma and thymomas, management of patients with a spectrum of neuro-endocrine thoracic tumors, and recent advances in immuno-oncology and targeted therapies in lung cancer. This symposium will review all of the recent advances in a highly interactive case-based discussion format, supported by didactic lectures by thought leaders and other well-respected faculty in each field.


After completing this activity, the participant will be able to;

  1. Apply the 8th edition of the IASLC staging system and utilize appropriate staging modalities to arrive at the correct stage to guide evidence-based treatment options.
  2. Identify lung cancer patients who are candidates for sublobar resection or proton beam therapy
  3. Analyze different technologies and processes utilized to maximize the efficiency of molecular profiling in thoracic oncology as it pertains to CAP guidelines for optimal biopsy considerations, tissue processing and test ordering sequence, and optimal turn-around-time for results
  4. Utilize the latest evidence based recommendations regarding utilization of biomarkers including PDL-1 testing and next generation sequencing to optimally sequence treatment options in non-small cell lung cancer.
  5. Explain the evolving data pertaining to immuno-oncology in lung cancer with emphasis on appropriate sequencing with chemotherapy and the role of potential biomarkers for immunotherapy
  6. Discuss recent advances and future directions in the development of targeted therapies for lung cancer
  7. Identify patient selection for multi-modality therapies with focus on small cell lung cancer, mesothelioma and thymoma